Data compiled by Redley Lamar · ChainSifter Intelligence
8Suppliers
5Customers
3Debt Items
0Related Chains
Source-Backed Evidence Depth
Calidi Biotherapeutics, Inc. (CLDI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
17Total relationships
2Distinct source URLs
12High confidence
0.813Average confidence
2026-07-01Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Calidi Biotherapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
COMPANY-A
COMPANY-A
92%
On December 13, 2024, the Company executed a Master Services Agreement with Company A, related to Director G, to engage Company A for contract research organization ("CRO") services and other clinica…
CITY-OF-HOPE
CITY-OF-HOPE
90%
We procured the neural stem cell bank from City of Hope and we extended the cell bank at a commercial ready CDMO.
GENSCRIPT-PROBIO
GENSCRIPT-PROBIO
90%
The CAL1virus for CLD-201 was manufactured at Genscript ProBio in China.
NORTHWESTERN-UNIVERSITY
NORTHWESTERN-UNIVERSITY
90%
On June 7, 2021, the Company entered into a License Agreement (the "Northwestern Agreement") with Northwestern University ("Northwestern") for the exclusive commercialization rights to the investigat…
STEMVAC
STEMVAC
90%
The development services provided by StemVac are highly specialized to meet our needs in developing a cost- and time-effective program as compared to services provided by an outsourced entity.
UNIVERSITY-OF-CHICAGO
UNIVERSITY-OF-CHICAGO
90%
On July 22, 2021, the Company entered into an Exclusive License Agreement with the University of Chicago (the "University of Chicago Agreement") for patents jointly owned by the University of Chicago…
VETSTEM-BIOPHARMA
VETSTEM-BIOPHARMA
90%
The AAA cell bank, VP-001, was produced by VetStem Biopharma.
EARLY-STAGE-CDMO
EARLY-STAGE-CDMO
80%
Pilot and/or initial GMP batches for both product candidates (CLD-101 and CLD-201), should those programs advance, are anticipated to be produced by an early-stage CDMO on an as-need basis.
Calidi Biotherapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
GERMANY-CALIDI-BIOTHERAPEUTICS-AUSTRALIA-PTY-LTD
GERMANY-CALIDI-BIOTHERAPEUTICS-AUSTRALIA-PTY-LTD
62%
isks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, possible failure of preclinical studies or clinical trials, the need to obtain mar…
NEVADA-CALIDI-BIOTHERAPEUTICS-INC-STEMVAC-GMBH
NEVADA-CALIDI-BIOTHERAPEUTICS-INC-STEMVAC-GMBH
62%
isks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, possible failure of preclinical studies or clinical trials, the need to obtain mar…
NOVA-CELL-INC
NOVA-CELL-INC
62%
isks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, possible failure of preclinical studies or clinical trials, the need to obtain mar…
NYSE-AMERICAN-LLC
NYSE-AMERICAN-LLC
62%
isks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, possible failure of preclinical studies or clinical trials, the need to obtain mar…
REDTAIL-BIOPHARMA-INC
REDTAIL-BIOPHARMA-INC
62%
isks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, possible failure of preclinical studies or clinical trials, the need to obtain mar…
Calidi Biotherapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CLDI-DEBT-8673
Warrants outstanding: 49440138
90%
xbrl warrant detail from xbrl 2026-03-31.
CLDI-DEBT-8674
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2024-12-31.
CLDI-DEBT
Debt stack $2.6M
90%
Market cache reports total debt of $2.6M.
Calidi Biotherapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Calidi Biotherapeutics, Inc..
Calidi Biotherapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
CLDI-OWNER-ARMISTICE-CAPITAL-LLC
ARMISTICE CAPITAL, LLC
90%
13F overlay lists ARMISTICE CAPITAL, LLC as top holder; 29 tracked holders.
Calidi Biotherapeutics, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
